James W. Brush, M.D.


Jamie is a Principal on the Frazier Life Sciences team and contributes to the full spectrum of Frazier investment activities, including private development stage companies, public equity, and new company creation.

Jamie joined Frazier Healthcare Partners in 2016 and focuses on investments in development-stage biotechnology companies. He led Frazier's investment in Translate Bio (NASDAQ: TBIO) and was involved in Frazier’s investments in Ignyta (acquired by Roche), ARMO (acquired by Eli Lilly), Amunix Pharmaceuticals, Bellicum Pharmaceuticals (NASDAQ: BLCM), Kezar Life Sciences (NASDAQ: KZR), Krystal Biotech (NASDAQ: KRYS), Recida Therapeutics, Sojournix and Synlogic (NASDAQ: SYBX).

Prior to joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing and business development strategy.

Jamie received his M.D. from the University of Southern California, where he was inducted into the Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his post-graduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston.

Menlo Park

Middlebury College (B.A.)
University of Southern California (M.D.)

Year Joined